ARPA-H launched THRIVE, a planned up-to-$160 million effort to develop custom gene editing treatments across rare diseases. The program will fund seven different teams, each with a stated milestone to begin clinical trials by year three. The agency’s focus is on tailoring gene editing “constructs” and approaches to specific disease biology, using partner teams to translate candidate designs into early clinical proof. THRIVE’s structure emphasizes parallel programs across organ systems, aiming to compress development timelines for indications with limited treatment options. The announcement highlights continued U.S. government interest in moving gene editing beyond platform innovation toward indication-specific therapeutics.